Phase II/III maintenance study of AJG501 in patients with ulcerative colitis
Phase 2
- Conditions
- lcerative colitis
- Registration Number
- JPRN-jRCT2080221044
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
UC in remission
Patients who received at least 1 treatment for induction of remission within the past 48 weeks.
Patients who diagnosed as mild to moderate UC in the nearest flare.
Patients who are in remission for 4 weeks or more.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Revised Sutherland DAI<br>Proportion of relapse-free
- Secondary Outcome Measures
Name Time Method